Cargando…

Hepatocyte Growth Factor and Cardiac Amyloidosis

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Ruberg, Frederick L., Siddiqi, Omar K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347296/ https://www.ncbi.nlm.nih.gov/pubmed/32647833 http://dx.doi.org/10.1016/j.jaccao.2020.02.004

Ejemplares similares

Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis
por: Gustine, Joshua N., et al.
Publicado: (2023)

Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis
por: Zhang, Kathleen W., et al.
Publicado: (2020)

Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following Stem Cell Transplantation
por: Lohrmann, Graham, et al.
Publicado: (2020)

Features of atrial fibrillation in wild‐type transthyretin cardiac amyloidosis: a systematic review and clinical experience
por: Mints, Yuliya Y., et al.
Publicado: (2018)

Comparison of right ventricular involvement in AL and transthyretin-type cardiac amyloidosis by cardiovascular magnetic resonance
por: Appelbaum, Evan, et al.
Publicado: (2009)

Hepatocyte growth factor, hepatocyte growth factor activator and arginine in a rat fulminant colitis model
por: Zwintscher, Nathan P., et al.
Publicado: (2016)

Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial
por: Minnema, Monique C., et al.
Publicado: (2022)

Implications of Extra-cardiac Disease in Patient Selection for Heart Transplantation: Considerations in Cardiac Amyloidosis
por: Punnoose, Lynn Raju, et al.
Publicado: (2023)

Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
por: Ruberg, Frederick L., et al.
Publicado: (2023)

Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis
por: Zampiccoli, Emanuel, et al.
Publicado: (2022)

Transthyretin Cardiac Amyloidosis: Underrecognized in the Underrepresented
por: Leedy, Douglas J., et al.
Publicado: (2023)

Cardiac Amyloidosis
por: Elbdri, Salah, et al.
Publicado: (2021)

Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
por: Madhani, Avni, et al.
Publicado: (2023)

Cardiac Amyloidosis Treatment
por: Stern, Lily K., et al.
Publicado: (2022)

Arrhythmias in Cardiac Amyloidosis
por: John, Roy M.
Publicado: (2018)

Atrial Involvement in Cardiac Amyloidosis: Beyond Dilatation
por: Fontana, Marianna, et al.
Publicado: (2020)

Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis
por: Kim, Darae, et al.
Publicado: (2020)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Prognostic Factors and Survival of Chinese Patients with Cardiac Amyloidosis
por: Zhang, Lu, et al.
Publicado: (2023)

Gateway and journey of patients with cardiac amyloidosis
por: Dang, Daniel, et al.
Publicado: (2020)

Hepatocyte Growth Factor and Clinical Diabetes in Postmenopausal Women
por: Rajpathak, Swapnil N., et al.
Publicado: (2010)

Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study
por: Schwartz, Brian, et al.
Publicado: (2022)

Rare Forms of Cardiac Amyloidosis: Diagnostic Clues and Phenotype in Apo AI and AIV Amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2023)

Catastrophic Cardiac Amyloidosis
por: Panduranga, Prashanth, et al.
Publicado: (2010)

Occult cardiac amyloidosis?
por: Westin, Oscar, et al.
Publicado: (2019)

Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021)

Fulminant cardiac amyloidosis
por: Real, Carlos, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Decoding the Nanoenvironment in Cardiac Amyloidosis Through Proteomics
por: Alexander, Kevin M., et al.
Publicado: (2020)

Hepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapies
por: Jiang, W.G.
Publicado: (2007)

Subtype‐Specific Interactions and Prognosis in Cardiac Amyloidosis
por: Sperry, Brett W., et al.
Publicado: (2016)

Incidence, Diagnosis and Prognosis of Cardiac Amyloidosis
por: Lee, Min-Ho, et al.
Publicado: (2013)

Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis
por: Donnellan, Eoin, et al.
Publicado: (2020)

Hepatocyte growth factor predicts failure of Fontan circulation
por: Kojima, Takuro, et al.
Publicado: (2020)

Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis
por: Takashio, Seiji, et al.
Publicado: (2017)

Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery–Associated Acute Kidney Injury
por: Ayad, Sabry, et al.
Publicado: (2020)

Cardiac MR elastography for quantitative assessment of elevated myocardial stiffness in cardiac amyloidosis
por: Arani, Arvin, et al.
Publicado: (2017)

Cardiovascular Magnetic Resonance and prognosis in cardiac amyloidosis
por: Maceira, Alicia M, et al.
Publicado: (2008)

Myocardial Oxygen Consumption and Efficiency in Patients With Cardiac Amyloidosis
por: Clemmensen, Tor Skibsted, et al.
Publicado: (2018)

Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis
por: Fischer, Kilian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bm5dhmnmke89321ebnmmbm3t83